These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25308565)

  • 1. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?
    Rahme C; Butterfield JM; Nicasio AM; Lodise TP
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
    Paul M; Silbiger I; Grozinsky S; Soares-Weiser K; Leibovici L
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003344. PubMed ID: 16437452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycosides versus beta-lactams in gram-negative pneumonia.
    Collins T; Gerding DN
    Semin Respir Infect; 1991 Sep; 6(3):136-46. PubMed ID: 1754734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.
    Jiao Y; Moya B; Chen MJ; Zavascki AP; Tsai H; Tao X; Sutaria DS; Louie A; Boyce JD; Deveson Lucas D; Kim TH; Tsuji BT; Bonomo RA; Drusano GL; Bulitta JB
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [News of antibiotic resistance among Gram-negative bacilli in Algeria].
    Baba Ahmed-Kazi Tani Z; Arlet G
    Pathol Biol (Paris); 2014 Jun; 62(3):169-78. PubMed ID: 24819127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.
    Falagas ME; Matthaiou DK; Bliziotis IA
    J Antimicrob Chemother; 2006 Apr; 57(4):639-47. PubMed ID: 16501057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is double coverage of gram-negative organisms necessary?
    Johnson SJ; Ernst EJ; Moores KG
    Am J Health Syst Pharm; 2011 Jan; 68(2):119-24. PubMed ID: 21200057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.
    Suárez CJ; Lolans K; Villegas MV; Quinn JP
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there evidence on the optimal duration of aminoglycoside therapy in β-lactam/aminoglycoside combination regimens used for the treatment of gram-negative bacterial infections? A systematic review.
    Wale YM; Roberts JA; Wolie ZT; Sime FB
    Int J Antimicrob Agents; 2024 Oct; 64(4):107297. PubMed ID: 39111709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Antibiotics in the Treatment of Urinary Tract Infections.
    Naber KG; Wagenlehner FME
    Eur Urol Focus; 2019 Jan; 5(1):10-12. PubMed ID: 30555037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.
    Veeraraghavan B; Pragasam AK; Bakthavatchalam YD; Anandan S; Ramasubramanian V; Swaminathan S; Gopalakrishnan R; Soman R; Abraham OC; Ohri VC; Walia K
    Indian J Med Microbiol; 2018; 36(3):334-343. PubMed ID: 30429384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vivo combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa].
    Sato K; Yamashita K; Okachi R
    Jpn J Antibiot; 1986 Jun; 39(6):1487-93. PubMed ID: 3093728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.
    Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME
    Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of resistance phenotypes in gram-negative bacteria].
    Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
    Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic considerations in using combinations of newer beta-lactam antibiotics.
    Barriere SL
    Clin Pharm; 1986 Jan; 5(1):24-33. PubMed ID: 3512153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.